Nutriband Inc logo

Nutriband Inc(NTRB)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$6.1
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NTRB

11/13/2026: NTRB (1-star) is currently NOT-A-BUY. Pass it for now.

Nutriband Inc is a small-cap pharmaceutical company focused on developing proprietary transdermal delivery systems, specifically its abuse-deterrent AVERSA platform. Its primary strength lies in its intellectual property and the clear, high-need market opportunity for safer drug delivery in pain management. However, the company faces significant execution and regulatory risks, and it currently lacks consistent commercial revenue. This stock is highly speculative and may best suit growth-oriented investors who can tolerate substantial volatility. Investors should monitor developments in FDA regulatory filings and any potential licensing deals with established pharmaceutical partners, as these events are crucial for the company's long-term commercial success.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThis is a speculative growth play dependent on future regulatory approvals rather than historical performance.
Momentum investorWeak fitThe stock lacks consistent trading volume and price momentum, making it less suitable for short-term momentum strategies.
Value investorWeak fitThe company lacks the earnings and asset base typical of traditional value investments.
Dividend investorWeak fitThe company does not pay dividends and focuses entirely on R&D.
Low-risk investorWeak fitThe high regulatory and execution risk inherent in early-stage biotech makes this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock is susceptible to sharp price swings based on clinical or regulatory news.
Valuation riskHighValuation is based on long-term potential rather than current financial output, increasing downside risk.
Competition risk (Pharmaceutical incumbents)HighLarge incumbents can outspend and outmaneuver the company in the market.
Business qualityMediumThe company has innovative intellectual property but lacks commercial-scale revenue.
Dividend incomeLow / noneThere is no dividend income for investors.
Execution riskHighFailure to achieve regulatory approval would severely impact the company's prospects.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 74.15M USD
Price to earnings Ratio -
1Y Target Price 15
Price to earnings Ratio -
1Y Target Price 15
Volume (30-day avg) 30.3K shares
Beta 2.18
52 Weeks Range 2.80 - 9.19
Updated Date 11/14/2026
52 Weeks Range 2.80 - 9.19
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.53

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 28.63%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NTRB receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
NTRB has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and moderate ownership. In FY2026 versus FY2025, solid earnings growth (+21.5%) is partially offset by weak cash generation (FCF margin -252.4%), slightly negative revenue growth (-4.8%), weak profitability (net margin -404.1%).

Financial Health Rating

★★★★★
NTRB's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 55.7%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is NTRB's strongest growth driver at +21.5% FY2026 versus FY2025 (solid, 4 stars). By comparison, while revenue growth (-4.8%, slightly negative) and free-cash-flow growth (-8.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 3.3% (soft) and 43.4% of outstanding shares are publicly tradable (moderate). Insider ownership of 59.20% supports management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 1.44%
Geode Capital Management, LLC 0.51%
Vanguard Fiduciary Trust Co 0.21%
State Street Corp 0.21%
Citadel Advisors Llc 0.16%

Unit Economics (Per $1K Revenue)

★★★★★
NTRB generates approximately $278 of gross profit, $-4,084 of operating income, and $-2,524 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
NTRB has a High Volatility Profile profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Transdermal Pharmaceutical ResearchLicensing fees and future royalty streams from the AVERSA platform.The company earns money by developing and potentially licensing its technology to larger pharma companies.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 370.37
Enterprise Value 69.13M
Price to Sales(TTM) 45.84
Enterprise Value 69.13M
Price to Sales(TTM) 45.84
Enterprise Value to Revenue 42.73
Enterprise Value to EBITDA -4.55
Shares Outstanding 12.16M
Shares Floating 5.28M
Shares Outstanding 12.16M
Shares Floating 5.28M
Percent Insiders 59.2
Percent Institutions 3.3

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.